

**DOCKET NO.: RTS-0242US.P1****PATENT****In the Specification**

In the previous amendment, the location of the paragraph below was incorrectly indicated in the response. The Applicants request that the previous amendment to the specification be withdrawn and that the language below be appropriately inserted in the specification as presently indicated. This version of the paragraph on page 130, line 4 to 25 will replace all prior versions of the paragraph in the specification:

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements can be designed to target superoxide dismutase-1, soluble. The nucleobase sequence of the antisense strand of the duplex comprises at least a portion of an oligonucleotide to superoxide dismutase-1, soluble as described herein. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini. For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

```
cgagaggcggacgggaccgTT
|||||
TTgctctccgcctgccctggc
```

Antisense Strand (SEQ ID NO: 340)

Complement (SEQ ID NO: 341)

**DOCKET NO.: RTS-0242US.P1****PATENT****In the Sequence Listing**

Please amend the sequence listing as follows:

&lt;210&gt; 341

<211> ~~15~~ 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 341

ttgctctccg cctgccctgg c

21